Skip to main content

Cuvrior FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 24, 2022.

FDA Approved: Yes (First approved April 28, 2022)
Brand name: Cuvrior
Generic name: trientine tetrahydrochloride
Dosage form: Tablets
Company: Orphalan SA
Treatment for: Wilson's Disease

Cuvrior (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.

Development timeline for Cuvrior

May  2, 2022Approval FDA Approves Cuvrior (trientine tetrahydrochloride) for the Treatment of Wilson’s disease
Jun 25, 2021Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.